Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations

• Published in: PloS one Vol. 13; no. 12; p. e0207625
• Main Authors: Real, Daniel, Hoffmann, Stefan, Leonardi, Darío, Salomon, Claudio, Goycoolea, Francisco M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 12-12-2018; Public Library of Science (PLoS)
• Subjects: Bioavailability; Biology and Life Sciences; Biopharmaceuticals; Biosensors; Caco-2 Cells; Cell Survival - drug effects; Chitosan; Chitosan - chemistry; Confocal microscopy; Cytotoxicity; Drug Carriers - chemistry; Drug Compounding; Drug delivery; Drug delivery systems; Drug development; Drug dosages; Drug Liberation; Drug Stability; Engineering and Technology; Formulations; Humans; Hydrogen-Ion Concentration; Medicine and Health Sciences; Microscopy; Nanocapsules - chemistry; Nanocrystals; Nanoemulsions; Nanoparticles; Nanotechnology; Oral administration; Parasites; Parasitic diseases; Particle size distribution; Pediatrics; Pharmaceuticals; Physical Sciences; Plant biology; Polydispersity; Research and Analysis Methods; Saline solutions; Scanning microscopy; Size distribution; Stability analysis; Tablets; Temperature; Toxicity; Triclabendazole - chemistry; Triclabendazole - pharmacology; Veterinary medicine; Zeta potential; Argentina; Germany
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0207625

Triclabendazole is a poorly-water soluble (0.24 μg/mL) compound classified into the Class II/IV of the Biopharmaceutical Classification System. It is the drug of choice to treat fascioliasis, a neglected parasitic disease worldwide disseminated. Triclabendazole is registered as veterinary medicine and it is only available for human treatment as 250 mg tablets. Thus, the aim of this work was to develop novel drug delivery systems based on nanotechnology approaches. The chitosan-based nanocapsules and nanoemulsions of triclabendazole were fully characterized regarding their particle size distribution, polydispersity index and zeta potential, in-vitro release and stability in biological media. Cytotoxicity evaluation and cellular uptake studies using CaCo-2 cell line were also investigated. The results indicated an average hydrodynamic size around ~160 nm were found for unloaded nanoemulsions which were slightly increased up to ~190 nm for loaded one. In contrast, the average hydrodynamic size of the nanocapsules increased from ~160 nm up to ~400 nm when loaded with triclabendazole. The stability studies upon 30 days storage at 4, 25 and 37°C showed that average size of nanoemulsions was not modified with varying amounts of loaded TCBZ while an opposite result was seen in case of loaded nanocapsules. In addition, a slight reduction of zeta potential values over time was observed in both triclabendazole nanosystems. Release of TCBZ from nanoformulations over 6 h in simulated gastric fluid was 9 to 16-fold higher than with untreated TCBZ dispersion. In phosphate buffer saline solution there was no drug release for neither nanocapsules nor nanoemulsions. Cell viabilities studies indicated that at certain concentrations, drug encapsulation can lower its cytotoxic effects when compared to untreated drug. Confocal laser scanning microscopy study has shown that nanocapsules strongly interacted with Caco-2 cells in vitro which could increase the passage time of triclabendazole after oral administration. The results of this study constitute the first step towards the development of nanoformulations intended for the oral delivery of anti-parasitic drugs of enhanced bioavailability.